Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient presenting with known or suspected enhancing abnormality(ies) and/or lesion(s) in at least one body region based on a previous imaging procedure performed within 12 months prior to ICF signature. US patients are restricted to the breast in compliance with local approved indications of gadobutrol.~Exclusion Criteria:~* Patient presenting with acute or chronic renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI (Type: EXPERIMENTAL): Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
- gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI (Type: EXPERIMENTAL): Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).